11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108078
Title:
11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group.
Authors:
Thatcher, Nick; Barber, Philip V; Hunter, Robin D; Carroll, K B; Jegarajah, S; Wilkinson, Peter M; Crowther, Derek
Abstract:
55 patients with inoperable but "limited"-stage small-cell carcinoma were treated sequentially with methotrexate, radiotherapy, and high doses of cyclophosphamide. The treatment was completed over 11 weeks and no maintenance chemotherapy was given. Follow-up lasted 9-29 months. Toxicity was acceptable, despite doses of cyclophosphamide of 1.5-3.5 g/m2. The complete response rate was 53%. Median survival for the total patient group was 12 months, range 2-29+. Patients who attained a complete response had a 17 month median survival; 17 patients remained in complete remission, 9 of whom first underwent treatment 14-29 months previously. Karnofsky performance scores improved after treatment and most patients were able to resume normal activity. The results are similar to those obtained with prolonged combination chemotherapy.
Citation:
11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. 1982, 1 (8280):1040-3 Lancet
Journal:
Lancet
Issue Date:
8-May-1982
URI:
http://hdl.handle.net/10541/108077; http://hdl.handle.net/10541/108078
PubMed ID:
6122853
Type:
Article
Language:
en
ISSN:
0140-6736
Appears in Collections:
All Christie Publications ; All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorBarber, Philip Ven
dc.contributor.authorHunter, Robin Den
dc.contributor.authorCarroll, K Ben
dc.contributor.authorJegarajah, Sen
dc.contributor.authorWilkinson, Peter Men
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-21T13:56:56Z-
dc.date.accessioned2010-07-21T13:56:57Z-
dc.date.available2010-07-21T13:56:56Z-
dc.date.available2010-07-21T13:56:57Z-
dc.date.issued1982-05-08-
dc.identifier.citation11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. 1982, 1 (8280):1040-3 Lanceten
dc.identifier.issn0140-6736-
dc.identifier.pmid6122853-
dc.identifier.urihttp://hdl.handle.net/10541/108077-
dc.identifier.urihttp://hdl.handle.net/10541/108078-
dc.description.abstract55 patients with inoperable but "limited"-stage small-cell carcinoma were treated sequentially with methotrexate, radiotherapy, and high doses of cyclophosphamide. The treatment was completed over 11 weeks and no maintenance chemotherapy was given. Follow-up lasted 9-29 months. Toxicity was acceptable, despite doses of cyclophosphamide of 1.5-3.5 g/m2. The complete response rate was 53%. Median survival for the total patient group was 12 months, range 2-29+. Patients who attained a complete response had a 17 month median survival; 17 patients remained in complete remission, 9 of whom first underwent treatment 14-29 months previously. Karnofsky performance scores improved after treatment and most patients were able to resume normal activity. The results are similar to those obtained with prolonged combination chemotherapy.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshCyclophosphamide-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMethotrexate-
dc.subject.meshTime Factors-
dc.title11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group.en
dc.typeArticleen
dc.identifier.journalLanceten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.